The effect of dosing time on efficacy and safety of an extended-release formulation of lovastatin in patients with primary hypercholesterolemia

Journal of Applied Research

Volumn 1, Issue 2, 2001, Pages

  Davidson, Michael H ^a   Lukacsko, Peter ^b   Sun, Jim X ^b   Phillips, Gale ^b   Walter, Ed ^b   Sterman, Arnold ^b   Friedhoff, Lawrence ^b  

^a RADIANT RESEARCH   (United States)

^b Watson Pharmaceuticals Inc   (United States)

Author keywords

Dosing time; Efficacy; Extended release; Lovastatin

Indexed keywords

EID: 0242408364     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Sun JX, Phillips G, Shen J, et al: Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans, [submitted to: J Clin Pharmacol 2001.]
2. Moghadasian MH: Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 65:1329-1337, 1999.
3. Bradford RH, Shear CL, Chremos AN, et al: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151:43-49, 1991.
4. Lovastatin Study Groups I Through IV. Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079-1087, 1993.
5. Mevacor [package insert]. Whitehouse Station, NJ, Merck & Co, Inc, 2000.
6. Davidson MH, Lukacsko P, Friedhoff L, Sterman A: A multiple-dose safety, pharmacokinetic, and pharmacodynamic study comparing an extended-release formulation of lovastatin with the immediaterelease formulation, [submitted to: Am J Cardiol 2001.]
7. Dobrinska MR, Stubbs RJ, Gregg MH, et al: Effects of dose and food on HMG-CoA reductase inhibitor profiles after lovastatin (Mevacor) [abstract]. Pharm Res 5(S-182): 1334, 1988.
8. Muck W, Frey R, Unger S, Voith B: Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening, Int J Clin Pharmacol Ther 38:298-303, 2000.
9. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
10. Roberts WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs [editorial]. Am J Cardiol 80:106-107, 1997.
11. Bradford RH, Shear CL, Chremos AN, et al: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 74:667-673, 1994.
12. Grouse JR, Lukacsko P, Niecestro R, and the Lovastatin Extended-Release Study Group: Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia. [submitted to: Am J Cardiol 2001.]
13. Gruer PJ, Vega JM, Mercuri MF, et al: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 84:811-815, 1999.